Participant flow

Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States · Source last updated 2019-09-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Three drug regimen using busulfan, and melphalan, and alemtuzumab. Busulfan, and melphalan, and alemtuzumab: intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT). Intravenous melphalan 100 mg/m2 on day -3. Intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1.

   id

   FG000

   title

   Busulfan, and Melphalan, and Alemtuzumab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         16

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice